- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| Do | VITA LIFE SCIENCES LIMITED: Capital Update-Vested Plan Shares | - | ASX | ||
| Do | VITA LIFE SCIENCES LIMITED: Cleansing Statement | - | ASX | ||
| Do | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | - | ASX | ||
| 10.04. | VITA LIFE SCIENCES LIMITED: Change of AGM Date | - | ASX | ||
| 09.04. | VITA LIFE SCIENCES LIMITED: Daily share buy-back notice - Appendix 3E | - | ASX | ||
| 26.03. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 21.03. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | 1 | ASX | ||
| 21.03. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | 1 | ASX | ||
| 18.03. | VITA LIFE SCIENCES LIMITED: Appendix 4G Corporate Governance Statement | - | ASX | ||
| 18.03. | VITA LIFE SCIENCES LIMITED: Annual Report to shareholders | - | ASX | ||
| 14.03. | VITA LIFE SCIENCES LIMITED: AGM Date and Closing Date for Directors' Nomination | - | ASX | ||
| 12.03. | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 1 | ASX | ||
| 26.02. | Australia's Vita Life Sciences hits 1-1/2-year high on upbeat FY results | 1 | Reuters | ||
| 26.02. | VITA LIFE SCIENCES LIMITED: Dividend/Distribution - VLS | 1 | ASX | ||
| 26.02. | VITA LIFE SCIENCES LIMITED: Full Year Results Presentation | 1 | ASX | ||
| 26.02. | VITA LIFE SCIENCES LIMITED: Preliminary Final Report | 1 | ASX | ||
| 13.02. | VITA LIFE SCIENCES LIMITED: Change in substantial holding | 1 | ASX | ||
| 14.12.23 | VITA LIFE SCIENCES LIMITED: Profit Guidance | - | ASX | ||
| 13.12.23 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 11,900 | +1,28 % | Green Thumb Industries: Aktie muss nachsetzen | Anzeige / WerbungLetztendlich blieben aber positive Impulse auf den Aktienkurs aus. Dabei wären diese dringend notwendig.Green Thumb Industries veröffentlichte am gestrigen Mittwoch (28. Februar) die... ► Artikel lesen | |
| INDIVA | 0,024 | +9,09 % | Indiva Ltd: Indiva to release 2023 results April 25 | ||
| ALNYLAM PHARMACEUTICALS | 138,10 | -0,68 % | Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC | SOUTH SAN FRANCISCO (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) presented KARDIA-2 Phase 2 study results of zilebesiran for the treatment of hypertension at the 2024 American College of... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,411 | -4,21 % | NKTR, VERU and EGIO among mid-day movers | ||
| CASSAVA SCIENCES | 19,855 | +5,47 % | CASSAVA SCIENCES INC - 8-K, Current Report | ||
| ADASTRA | 0,144 | -2,70 % | Adastra Holdings Ltd.: Adastra Holdings Announces Lachlan McLeod as Interim CEO | LANGLEY, BC / ACCESSWIRE / April 15, 2024/ Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian concentrates brands... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 16,200 | +1,95 % | Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals | ||
| SELLAS LIFE SCIENCES | 1,308 | +5,65 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,048 | -9,43 % | Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results | Q2 Fiscal 2024 Highlights
Cash position of $6.6 million as of February 29, 2024
Gross profit of $0.5 million, a 22.7% decline over Q1 2024
Revenue of $5.0 million, a 15.4% decline over Q1 2024
Enrolment... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 14,695 | +1,38 % | Santhera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten | AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten ab 2 Jahren erhältlichDies folgt auf die erste kommerzielle Einführung... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | XFRA ERV2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMOLECULE HOLDINGS... ► Artikel lesen | |
| SOLIGENIX | 0,474 | 0,00 % | SOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection | Provides MarVax Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval
PRINCETON, N.J., April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)... ► Artikel lesen | |
| OCUPHIRE PHARMA | 1,688 | +1,32 % | Ocuphire Pharma: First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery | LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP)... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,420 | -0,94 % | ZELIRA THERAPEUTICS LIMITED: Zelira receives $919,000 R&D Tax Incentive Scheme Refund | ||
| ANI PHARMACEUTICALS | 62,50 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension | BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
